<DOC>
	<DOCNO>NCT01523847</DOCNO>
	<brief_summary>The study purpose evaluate elderly and/or cardiopathic HL patient , cardiologic toxicity MBVD regimen , liposomal doxorubicin ( Myocet® ) substitute doxorubicin conventional ABVD regimen .</brief_summary>
	<brief_title>A Multi-centre Study MBVD Elderly and/or Cardiopathic Patients Affected Hodgkin 's Lymphoma ( HL )</brief_title>
	<detailed_description>STUDY POPULATION Patients affect Hodgkin 's lymphoma , stage , old 69 year . Patients affect Hodgkin 's Lymphoma concomitant cardiopaty , old 18 year . AIMS OF THE STUDY - To evaluate elderly and/or cardiopathic HL patient , cardiologic toxicity MBVD regimen , liposomal doxorubicin ( Myocet® ) substitute doxorubicin conventional ABVD regimen - To compare pair-match retrospective analysis result obtain MBVD obtain patient comparable clinical variable treat ABVD reduce intensity VEPEMB schedule . STUDY DESIGN Multi-centre phase II study SAMPLE SIZE 50 patient STUDY PROCEDURES - Histologic diagnosis Hodgkin Lymphoma . - Early Staging evaluation include : - Blood test - CT , PET bone marrow biopsy . - Heart lung function evaluation . - Geriatric assessment . - Quality life evaluation . - 2 MBVD course - Early restaging PET scan ( PET-2 ) - The subsequent treatment plan follow : - Stage I IIA patient go 1 course MBVD ( total 3 course ) follow involved field radiotherapy ( 30 Gy-36Gy ) . - Advanced stage ( IIB-IV ) patient go 4 course MBVD ( total 6 course ) . Radiotherapy limit bulky non complete responder area ( 30-36 Gy ) optional . - Final restaging include : - Blood test - CT , PET - bone marrow biopsy positive baseline . - Heart lung function evaluation . - Geriatric assessment . - Quality life evaluation Follow procedure include : 1. clinical laboratory evaluation ( troponin , proBNP / BNP , cardiology visit , ECG echocardiogram ) every 6 month first 2 year , annually . 2 . CT scan plan annually . 3 . Compilation geriatric evaluation scale every 6 month first 2 year , annually . MBVD schedule follow ( 4 week ) : Myocet 25 mg/mq i.v . day 1 15 Bleomycin 10 mg/mq i.v . day 1 15 Vinblastine 6 mg/mq i.v . day 1 15 Dacarbazine 375 mg/mq i.v . day 1 15 Supportive treatment G-CSF and/or Erythropoietin plan accord international guide-lines .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>Histologically confirm Hodgkin 's lymphoma , except nodular lymphocyte predominance subgroup . Previously untreated Age ≥ 70 . Age &gt; 18 presence cardiopathy accord inclusion criteria… Patients HCV HBV infection include . For patient HBV+ occult carrier ( AntiHBc+ , HbsAg , AntiHBs+/ ) Lamivudine prophylaxis mandatory . Life expectancy &gt; 3 month Informed consent . Staging PETCT . Preliminary geriatric assessment ( ADL , IADL , comorbidity frailness score ) . Lymphocyte predominance subgroup Age &lt; 70 ( cardiopathy ) Age &lt; 18 ( cardiopathy ) . HIV infection . Previous treatment Hodgkin 's lymphoma . Other concomitant previous malignancy , exception basal cell skin tumor , adequately treat carcinoma situ cervix cancer complete remission &gt; 5 year . Renal failure ( creatinine high twice normal level ) liver disease ( AST/ALT bilirubin level high 2.5 time normal level ) Other clinical situation contraindicate , judgment investigator , administration milddose chemotherapy . Isolated comorbidities score record , , isolate , sufficient reason exclusion . Frail patient , define accord comorbidity scale : patient 1 grade 4 comorbidity , &gt; 3 grade 3 comorbidities , exclude . ( see appendix.6 ) Unresponsive sepsis Dementia Impossibility subscribe inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Hodgkin Lymphoma</keyword>
	<keyword>Cardiopathic</keyword>
	<keyword>elderly</keyword>
	<keyword>Myocet</keyword>
</DOC>